Altimmune, Inc. (30)

Browse by Contract Category

Contracts

Amendment No. 7 Contract Award issued by the Biomedical Advanced Research and Development Authority of the United Sates Department of Health and Human Services, dated June 29, 2021 (Filed With SEC on August 10, 2021)
Statement of Work, dated March 9, 2021, by and between Altimmune, Inc. and Lonza Houston Inc (Filed With SEC on May 17, 2021)
Amendment No. 6 to the Second Restated License Agreement, effective as of January 22, 2021, between Janssen Vaccines & Prevention B.V. (formerly Crucell Holland B.V.) and... (Filed With SEC on May 17, 2021)
Exchange Agreement between Altimmune, Inc. and Venrock Healthcare Capital Partners II, L.P., Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings II, LLC and... (Filed With SEC on February 25, 2021)
Non-Employee Director Compensation Policy (Filed With SEC on November 9, 2020)
Agreement and Plan of Merger and Reorganization, dated July 8, 2019, by and among Altimmune, Inc., Springfield Merger Sub, Inc., Springfield Merger Sub, LLC, Spitfire Pharma, Inc.... (Filed With SEC on July 9, 2019)
Form of Pre-Funded Warrant (Filed With SEC on February 25, 2021)
Equity Distribution Agreement, dated February 25, 2021, by and among Altimmune, Inc. and Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc (Filed With SEC on February 25, 2021)
Amendment No. 6 to Contract Award issued by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services, dated December... (Filed With SEC on February 25, 2021)
Amendment No. 5 to Second Restated License Agreement, effective as of October 22, 2020, between Janssen Vaccines & Prevention B.V. (formerly Crucell Holland B.V.) and Altimmune,... (Filed With SEC on February 25, 2021)
Description of Registrants Securities (Filed With SEC on February 25, 2021)
Amendment No. 4 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of July 28, 2020 (Filed With SEC on November 9, 2020)
Amendment No. 3 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of April 2, 2020 (Filed With SEC on August 11, 2020)
Amendment No. 2 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of September 20, 2016 (Filed With SEC on August 11, 2020)
Form of Pre-Funded Warrant (Filed With SEC on July 16, 2020)
Underwriting Agreement, dated as of July 13, 2020, among Altimmune, Inc. and Jefferies LLC, Evercore Group L.L.C. and Piper Sandler & Co., as representatives of the underwriters... (Filed With SEC on July 16, 2020)
Equity Distribution Agreement, dated March 27, 2020, by and among Altimmune, Inc. and JMP Securities LLC (Filed With SEC on March 27, 2020)
Description of Registrants Securities (Filed With SEC on March 27, 2020)
Employment Agreement, dated September 3, 2019, by and between the Company and M. Scott Harris, M.D (Filed With SEC on November 13, 2019)
Amendment No. 5 to Contract Award issued by Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services, dated August 20,... (Filed With SEC on November 13, 2019)
Amended and Restated License Agreement, dated July 12, 2019, by and between Mederis Diabetes, LLC and Spitfire Pharma, Inc (Filed With SEC on November 13, 2019)
Release of Claims Agreement, by and between the Company and Dr. Tasker, dated June 17, 2019 (Filed With SEC on August 13, 2019)
Transition Services Agreement, by and between the Company and Sybil Tasker, M.D., MPH, dated June 17, 2019 (Filed With SEC on August 13, 2019)
Form of Lock-Up Agreement (Filed With SEC on July 9, 2019)
Employment Agreement, dated June 10, 2019, by and between Altimmune, Inc. and William Brown (Filed With SEC on June 12, 2019)
Amendment, dated March 14, 2019, to Consulting Agreement, dated May 21, 2018, by and between Altimmune Inc., and William Brown (Filed With SEC on March 15, 2019)
Form of Pre-funded Warrant (Filed With SEC on March 11, 2019)
Form of Securities Purchase Agreement among Altimmune, Inc. and certain investors (Filed With SEC on March 11, 2019)
Form of Warrant (Filed With SEC on March 11, 2019)
Placement Agency Agreement among Altimmune, Inc. and Roth Capital Partners, LLC (Filed With SEC on March 11, 2019)